These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1378111)

  • 21. Effects of SUN-1165, N-(2,6-dimethylphenyl)-8-pyrrolizidine acetamide hydrochloride hemihydrate, a new class I antiarrhythmic drug, on ventricular arrhythmias, intraventricular conduction, and the refractory period in canine myocardial infarction.
    Hashimoto H; Satoh N; Nakashima M
    J Cardiovasc Pharmacol; 1992 Mar; 19(3):417-24. PubMed ID: 1378123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrophysiologic and hemodynamic effects of propafenone, a new antiarrhythmic agent, on the anesthetized, closed-chest dog: comparative study with lidocaine.
    Karagueuzian HS; Katoh T; McCullen A; Mandel WJ; Peter T
    Am Heart J; 1984 Mar; 107(3):418-24. PubMed ID: 6695682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiarrhythmic and arrhythmogenic actions of methyl lidocaine during the recovery phase after canine myocardial infarction.
    Patterson E; Gibson JK; Lucchesi BR
    Pharmacology; 1988; 36(2):73-83. PubMed ID: 3353442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative hemodynamic effects of Org 7797, flecainide, and propafenone in anesthetized pigs with developing myocardial infarcts.
    Winslow E; Mason R
    J Cardiovasc Pharmacol; 1992 Mar; 19(3):435-41. PubMed ID: 1378126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arrhythmogenic effects of antiarrhythmic drugs in patients with an old myocardial infarction and asymptomatic ventricular ectopic activity as studied by programmed electrical stimulation.
    Farré J; Grande A; Albo PS; Martí F; Martínez-Romero P; Alfonso F; Rábago P
    Eur Heart J; 1987 Mar; 8 Suppl A():113-9. PubMed ID: 2438133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone.
    Malfatto G; Zaza A; Forster M; Sodowick B; Danilo P; Rosen MR
    J Pharmacol Exp Ther; 1988 Aug; 246(2):419-26. PubMed ID: 3404440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of prenylamine and AQ-A 39 on reentrant ventricular arrhythmias induced during the late myocardial infarction period in conscious dogs.
    Aidonidis I; Egel E; Hilbel T; Kuebler W; Brachmann J
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):401-7. PubMed ID: 7504130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of associated propafenone in patients with amiodarone-resistant ventricular tachycardia.
    Morgera T; Dreas L; Humar F; Maras P; Chersevani D; Camerini F
    Int J Cardiol; 1991 May; 31(2):187-97. PubMed ID: 1869328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of acute ischemia, early extrabeats and propafenone on complex activation patterns in intact and ischemic canine hearts.
    Bauer A; Becker R; Voss F; Senges JC; Kraft P; Schreiner KD; Kuebler W; Schoels W
    Life Sci; 2003 May; 72(24):2751-67. PubMed ID: 12679192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiarrhythmic and electrophysiologic effects of oral propafenone.
    Prystowsky EN; Heger JJ; Chilson DA; Miles WM; Hubbard J; Zipes DP
    Am J Cardiol; 1984 Nov; 54(9):26D-28D. PubMed ID: 6496366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model.
    Kondoh K; Hashimoto H; Nishiyama H; Umemura K; Ozaki T; Uematsu T; Nakashima M
    J Cardiovasc Pharmacol; 1994 Apr; 23(4):674-80. PubMed ID: 7516022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac electrophysiological effects of propafenone and its 5-hydroxylated metabolite in the conscious dog.
    Boucher M; Chassaing C; Hamel JD; Poirier JM
    Eur J Pharmacol; 1996 Nov; 315(2):171-7. PubMed ID: 8960881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Programmed electrical stimulation after myocardial infarction and reperfusion in conscious dogs.
    Krumpl G; Todt H; Schunder-Tatzber S; Raberger G
    J Pharmacol Methods; 1990 Apr; 23(2):155-69. PubMed ID: 2332981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia.
    Manz M; Steinbeck G; Lüderitz B
    Am J Cardiol; 1985 Oct; 56(10):593-7. PubMed ID: 4050693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia.
    Kamiya J; Ishii M; Katakami T
    Jpn J Pharmacol; 1992 Feb; 58(2):107-15. PubMed ID: 1507517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
    Harron DW; Brogden RN
    Drugs; 1987 Dec; 34(6):617-47. PubMed ID: 3322781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed electrical stimulation in conscious dogs: electropharmacologic testing of amrinone.
    Todt H; Krumpl G; Krejcy K; Schunder-Tatzber S; Raberger G
    Arch Int Pharmacodyn Ther; 1990; 307():32-48. PubMed ID: 2095712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Na+ channel blockers vs class III antiarrhythmic drugs in treating sustained ventricular tachycardia: reversing and preventing as different electrophysiological mechanisms.
    Masotti CS; Pierangeli A
    Panminerva Med; 1999 Dec; 41(4):295-306. PubMed ID: 10705709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation.
    Podczeck A; Frohner K; Hief C; Stix G; Steinbach KK
    Eur Heart J; 1991 Jul; 12(7):796-9. PubMed ID: 1889445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiarrhythmic and electrophysiologic effects of MDL 11,939, a novel class III antiarrhythmic agent in anesthetized dogs.
    Koerner JE; Dage RC
    J Cardiovasc Pharmacol; 1990 Sep; 16(3):383-93. PubMed ID: 1700208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.